CatalystAlert

Search CatalystAlert

Search for companies, drugs, and catalysts

Search CatalystAlert

Search for companies, drugs, and catalysts

BioPharma Dive
Original article

Alnylam plunges as earnings deliver ‘one-two punch’

EarningsNegative
AI Analysis

Summary

Alnylam shares plunged 30% (approximately $12 billion in market value) following earnings results that revealed growing investor concerns about its main drug business.

Importance:6/10
Sentiment:
-0.90
earningsstock_declineRNA_therapeuticsbusiness_concerns
Related Companies

Read the original article

Published by BioPharma Dive on July 30, 2026 8:12 PM

Read Original